文献速递艾滋病与性传播感染结核与非结核分枝杆菌

双倍剂量多替拉韦在接受利福平为基础结核治疗人群中的有效性:来自6个国家HIV感染者的观察性队列研究

Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries.
PubMed 文献 · Clin Infect Dis · 2025-01-01

在6个国家12个中心开展前瞻性观察性队列研究,纳入91例结核/HIV共感染参与者,在接受含利福平结核治疗的同时启动替诺福韦-拉米夫定-多替拉韦并额外加用50 mg多替拉韦。73例可评估者中69例(95%;95%CI 89%-100%)在结核治疗结束时HIV-1 RNA≤1000 copies/mL,4例HIV-1 RNA>1000 copies/mL者未检出多替拉韦耐药突变。

要点

  • 含利福平结核治疗期间联用替诺福韦-拉米夫定-多替拉韦并额外加用50 mg多替拉韦,在项目化条件下可行且耐受良好。
  • 73例可评估参与者中69例(95%;95%CI 89%-100%)在结核治疗结束时HIV-1 RNA≤1000 copies/mL。
  • 4例HIV-1 RNA>1000 copies/mL的参与者中未检出多替拉韦耐药突变。

核心结论

  • 在项目化条件下,含利福平结核治疗与替诺福韦-拉米夫定-多替拉韦并额外加用50 mg多替拉韦同时使用可行、耐受良好,在以未接受过抗逆转录病毒治疗者为主的结核/HIV共感染队列中达到高病毒抑制率。

研究设计与样本

  • 前瞻性观察性队列研究,在12个中心开展,中心位于海地、肯尼亚、马拉维、南非、乌干达和津巴布韦。
  • 纳入91例开始替诺福韦-拉米夫定-多替拉韦并接受含利福平结核治疗的参与者。
  • 主要结局为结核治疗结束时HIV-1 RNA≤1000 copies/mL。

主要发现

  • 91例结核/HIV参与者中,75例(82%)为未接受过抗逆转录病毒治疗者,在结核治疗中位15天后启动替诺福韦-拉米夫定-多替拉韦。
  • 10例(11%)为未接受过抗逆转录病毒治疗者,同时启动替诺福韦-拉米夫定-多替拉韦和结核治疗。
  • 5例(5%)在替诺福韦-拉米夫定-多替拉韦中位治疗3.3年后启动结核治疗;1例(1%)从依非韦伦-拉米夫定-替诺福韦更换后同时启动结核治疗和替诺福韦-拉米夫定-多替拉韦。
  • 中位年龄37岁,35%为女性,中位CD4计数120 cells/mm3(四分位距50-295),87%的参与者HIV-1 RNA>1000 copies/mL。
  • 89例存活参与者中80例随访至结核治疗完成,其中7例因错过访视无HIV-1 RNA结果;73例参与者评估了主要病毒学结局,其中69例(95%;95%CI 89%-100%)HIV-1 RNA≤1000 copies/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen. An additional 50-mg dose of dolutegravir (TLD+50) is required with rifampin-containing tuberculosis (TB) co-treatment. There are limited data on the effectiveness of TLD+50 in individuals with TB/human immunodeficiency virus (HIV). METHODS: We performed a prospective, observational cohort study at 12 sites in Haiti, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. Participants starting TLD and rifampin-containing TB treatment were eligible. The primary outcome was HIV-1 RNA ≤1000 copies/mL at end of TB treatment. RESULTS: We enrolled 91 participants with TB/HIV: 75 (82%) ART-naive participants starting TLD after a median 15 days on TB treatment, 10 (11%) ART-naive participants starting TLD and TB treatment, 5 (5%) starting TB treatment after a median 3.3 years on TLD, and 1 (1%) starting TB treatment and TLD after changing from efavirenz-lamivudine-tenofovir. Median age was 37 years, 35% were female, the median CD4 count was 120 cells/mm3 (interquartile range, 50-295), and 87% had HIV-1 RNA >1000 copies/mL. Among 89 surviving participants, 80 were followed to TB treatment completion, including 7 who had no HIV-1 RNA result due to missed visits. The primary virologic outcome was assessed in 73 participants, 69 of whom (95%; 95% confidence interval, 89%-100%) had HIV-1 RNA ≤1000 copies/mL. No dolutegravir resistance mutations were detected among 4 participants with HIV-1 RNA >1000 copies/mL. CONCLUSIONS: In programmatic settings, concurrent rifampin-containing TB treatment and TLD+50 was feasible, well tolerated, and achieved high viral suppression rates in a cohort of predominantly ART-naive people with TB/HIV.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Shah NS, Kityo C, Hughes MD, et al. Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries. Clin Infect Dis. 2025. PMID: 38739755. doi:10.1093/cid/ciae269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。